Coleen Glessner - 03 Mar 2026 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role: EVP, Quality & Ethics, and CPL
Signature: /s/ Richard S. Lindahl, Attorney-in-fact
Issuer symbol: EBS
Transactions as of: 03 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 05 Mar 2026, 21:06:04 UTC
Previous filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Glessner Coleen	EVP, Quality & Ethics, and CPL	300 PROFESSIONAL DRIVE, GAITHERSBURG	/s/ Richard S. Lindahl, Attorney-in-fact	05 Mar 2026	0001919170

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EBS	Common Stock	Tax liability		-8,199	-7.3%	$8.44^*	104,108	05 Mar 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EBS	Employee Stock Option (Right to buy)	Award		+44,834	+18%	$0.000000^*	294,447	03 Mar 2026	Common Stock	44,834	$8.99	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
F2	Vests in three equal installments beginning on the day prior to the anniversary date of the grant.